← Oncology Approval Tracker

FDA DECISION ·

Bynfezia Pen

octreotide acetate · Sun Pharmaceutical Industries

FDA approvalReapprovalCarcinoid syndrome and VIPoma-associated diarrhea
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Subcutaneous octreotide pen for severe diarrhea and flushing due to metastatic carcinoid tumors and profuse watery diarrhea from vasoactive intestinal peptide-secreting tumors. The pen also has a separate acromegaly indication.

LAMPGEN ANALYSIS

Why it matters

FDA reapproved the pen after rescinding its 2020 approval. The reapproval followed a new submission addressing manufacturing compliance.

What research teams should watch

Train patients on pen setup, dose measurement and disposal, and track symptom control and short-acting treatment use.

PRIMARY RECORDS

Sources